Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Harukuni, I.
Right arrow Articles by Faraci, F. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Harukuni, I.
Right arrow Articles by Faraci, F. M.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*HALOPERIDOL
Related Collections
Right arrow Brain Circulation and Metabolism
Right arrow Emergency treatment of Stroke
Right arrow Neuroprotectors
Right arrow Other Stroke Treatment - Medical

(Stroke. 2000;31:976.)
© 2000 American Heart Association, Inc.


Original Contributions

{sigma}1-Receptor Ligand 4-Phenyl-1-(4-Phenylbutyl)-Piperidine Affords Neuroprotection From Focal Ischemia With Prolonged Reperfusion

Izumi Harukuni, MD; Anish Bhardwaj, MD; Amanda B. Shaivitz, BA; A. Courtney DeVries, PhD; Edythe D. London, PhD; Patricia D. Hurn, PhD; Richard J. Traystman, PhD Jeffrey R. Kirsch, MD

From the Departments of Anesthesiology/Critical Care Medicine (I.H., A.B., A.B.S., A.C.D., P.D.H., R.J.T., J.R.K.) and Neurology (A.B., J.R.K.), Johns Hopkins University School of Medicine, Baltimore, Md, and National Institute on Drug Abuse (E.D.L.), Baltimore, Md.

Correspondence to Jeffrey R. Kirsch, MD, Blalock 1412, Johns Hopkins Hospital, 600 N Wolfe St, Baltimore, MD 21287-4963. E-mail jkirsch{at}jhmi.edu

Background and Purpose—We previously showed that the intravenous administration of the potent {varsigma}1-receptor ligand 4-phenyl-1-(4-phenylbutyl)-piperidine (PPBP) provides neuroprotection against transient focal cerebral ischemia and that the protection depends on treatment duration. We tested the hypothesis that PPBP would provide neuroprotection in a model of transient focal ischemia and 7 days of reperfusion in the rat as assessed with neurobehavioral outcome and infarction volume.

Methods—Under the controlled conditions of normoxia, normocarbia, and normothermia, halothane-anesthetized male Wistar rats were subjected to 2 hours of middle cerebral artery occlusion (MCAO) with the intraluminal suture occlusion technique. We used laser Doppler flowmetry to assess MCAO. At 60 minutes after the onset of ischemia, rats were randomly assigned to 1 of 4 treatment groups in a blinded fashion and received a continuous intravenous infusion of control saline or 0.1, 1, or 10 µmol · kg-1 · h-1 PPBP for 24 hours. Neurobehavioral evaluation was performed at baseline (3 to 4 days before MCAO) and at 3 and 7 days of reperfusion. Infarction volume was assessed with triphenyltetrazolium chloride staining on day 7 of reperfusion in all rats.

Results—Triphenyltetrazolium chloride–determined infarction volume of ipsilateral cortex was smaller in rats treated with 10 µmol · kg-1 · h-1 PPBP (n=15, 68±12 mm3, 18±3% of contralateral structure, P<0.05) (mean±SEM) compared with corresponding rats treated with saline (n=15, 114±11 mm3, 31±3% of contralateral structure). PPBP did not provide significant neuroprotection in the caudoputamen complex. Although MCAO was associated with several alterations in behavior, the treatment with PPBP had no effect on behavioral outcomes.

Conclusions—The data demonstrate that the potent {varsigma}1-receptor ligand PPBP decreases cortical infarction volume without altering neurobehavior after transient focal ischemia and prolonged reperfusion in the rat.

Editorial Comment

Frank M. Faraci, PhD, Guest Editor

Department of Internal Medicine, Cardiovascular Division, University of Iowa College of Medicine, Iowa City, Iowa




This article has been cited by other articles:


Home page
Anesth. Analg.Home page
S. Yang, A. Bhardwaj, J. Cheng, N. J. Alkayed, P. D. Hurn, and J. R. Kirsch
Sigma Receptor Agonists Provide Neuroprotection In Vitro by Preserving bcl-2
Anesth. Analg., May 1, 2007; 104(5): 1179 - 1184.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
J. Meunier, J. Ieni, and T. Maurice
Antiamnesic and Neuroprotective Effects of Donepezil against Learning Impairments Induced in Mice by Exposure to Carbon Monoxide Gas
J. Pharmacol. Exp. Ther., June 1, 2006; 317(3): 1307 - 1319.
[Abstract] [Full Text] [PDF]


Home page
Anesth. Analg.Home page
T. Goyagi, A. Bhardwaj, R. C. Koehler, R. J. Traystman, P. D. Hurn, and J. R. Kirsch
Potent {sigma}1-Receptor Ligand 4-Phenyl-1-(4-Phenylbutyl) Piperidine Provides Ischemic Neuroprotection Without Altering Dopamine Accumulation In Vivo in Rats
Anesth. Analg., February 1, 2003; 96(2): 532 - 538.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
T. Goyagi, S. Goto, A. Bhardwaj, V. L. Dawson, P. D. Hurn, and J. R. Kirsch
Neuroprotective Effect of {{sigma}}1-Receptor Ligand 4-Phenyl-1-(4-Phenylbutyl) Piperidine (PPBP) Is Linked to Reduced Neuronal Nitric Oxide Production
Stroke, July 1, 2001; 32(7): 1613 - 1620.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
R. J. Traystman, J. A. Klaus, A. C. DeVries, A. B. Shaivitz, and P. D. Hurn
Anticonvulsant Lamotrigine Administered on Reperfusion Fails To Improve Experimental Stroke Outcomes
Stroke, March 1, 2001; 32(3): 783 - 787.
[Abstract] [Full Text] [PDF]